SciELO - Scientific Electronic Library Online

 
vol.145 número6Desigualdad en recursos financieros de la Atención Primaria de Salud Municipal en Chile, 2001-2013Determinación de la reserva ovárica mediante el recuento de folículos antrales en mujeres en edad reproductiva índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google

Compartilhar


Revista médica de Chile

versão impressa ISSN 0034-9887

Resumo

ROSSEL, Víctor et al. Galectina-3: experiencia en pacientes chilenos con diagnóstico de insuficiencia cardíaca descompensada. Rev. méd. Chile [online]. 2017, vol.145, n.6, pp.734-740. ISSN 0034-9887.  http://dx.doi.org/10.4067/s0034-98872017000600734.

Background:

Galectin-3 (Gal-3) is a mediator of myocardial fibrosis involved in cardiac remodeling and a potential new prognosis marker in heart failure (HF). Aim: To measure Gal-3 at the moment of discharge in patients hospitalized for HF and its association with different variables.

Material and Methods:

Patients hospitalized for decompensated HF from four hospitals between August 2014 and March 2015, were included. Demographic, clinical and laboratory variables were recorded at the time of admission. At discharge, a blood sample was withdrawn to measure Gal-3 and brain natriuretic propeptide (Pro-BNP). Patients were separated in two groups, according to the level of Gal-3 (using a cutoff value of 17.8 ng/mL), comparing clinical and laboratory values between groups.

Results:

We included 52 patients with HF aged 70 ± 17 years (42% females). Functional capacity was III-IV in 46% of patients and the ejection fraction was 34.9 ± 13.4%. Pro-BNP values at discharge were 5,323 ± 8,665 pg/mL. Gal-3 values were 23.8 ± 16.6 ng/mL. Sixty percent of patients had values over 17.8 ng/mL. Those with elevated Gal-3 levels were older (75 ±16 and 62 ± 15 years, respectively, p = 0.025) and were hypertensive in a higher proportion (90.5% and 57.1% respectively, p = 0.021).

Conclusions:

In patients hospitalized for HF, Gal-3 levels are higher in older and hypertensive subjects.

Palavras-chave : Biomarkers; Galectin-3; Heart Failure.

        · texto em Espanhol     · Espanhol ( pdf )